These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37651156)

  • 21. Cutaneous T-cell lymphoma at a young age.
    Roszkiewicz J; Roszkiewicz A; Wojdylo M; Placek W; Jasiel-Walikowska E
    Cutis; 2001 Mar; 67(3):197-200, 203-4. PubMed ID: 11270292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New biologic agents for the treatment of cutaneous T-cell lymphoma.
    Vittorio CC; Junkins-Hopkins JM; McGinnis KS; Shapiro M; Wysocka M; Zaki MH; French LE; Rook AH
    Recent Results Cancer Res; 2002; 160():321-8. PubMed ID: 12079230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 24. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL).
    Burg G; Dummer R
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S41-4. PubMed ID: 11707863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin infiltrating NK cells in cutaneous T-cell lymphoma are increased in number and display phenotypic alterations partially driven by the tumor.
    Scheffschick A; Nenonen J; Xiang M; Winther AH; Ehrström M; Wahren-Herlenius M; Eidsmo L; Brauner H
    Front Immunol; 2023; 14():1168684. PubMed ID: 37691935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological analysis of 17 primary cutaneous T-cell lymphoma of the γδ phenotype from Japan.
    Takahashi Y; Takata K; Kato S; Sato Y; Asano N; Ogino T; Hashimoto K; Tashiro Y; Takeuchi S; Masunari T; Hiramatsu Y; Maeda Y; Tanimoto M; Yoshino T
    Cancer Sci; 2014 Jul; 105(7):912-23. PubMed ID: 24815502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical treatment of early cutaneous T-cell lymphoma.
    Ramsay DL; Meller JA; Zackheim HS
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced/aggressive CTCL: improving the efficacy of treatment.
    Zinzani PL
    G Ital Dermatol Venereol; 2012 Dec; 147(6):563-72. PubMed ID: 23149702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients.
    Affandi AM; Blumetti TP; Wells J; Hertzberg M; Fernandez-Peñas P
    Australas J Dermatol; 2015 Nov; 56(4):294-7. PubMed ID: 25496219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma.
    Su IJ; Tsai TF; Cheng AL; Chen CC
    J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development.
    Mirza FN; Yumeen S; Lewis JM; King ALO; Kim SR; Carlson KR; Umlauf S; Surovtseva YV; Foss FM; Girardi M
    J Invest Dermatol; 2021 Jan; 141(1):217-221. PubMed ID: 32534802
    [No Abstract]   [Full Text] [Related]  

  • 34. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
    Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
    Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.
    Zhang XH; Nam S; Wu J; Chen CH; Liu X; Li H; McKeithan T; Gong Q; Chan WC; Yin HH; Yuan YC; Pillai R; Querfeld C; Horne D; Chen Y; Rosen ST
    J Invest Dermatol; 2018 Nov; 138(11):2377-2387. PubMed ID: 29758280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dimethyl fumarate suppresses metastasis and growth of melanoma cells by inhibiting the nuclear translocation of NF-κB.
    Takeda T; Tsubaki M; Asano R; Itoh T; Imano M; Satou T; Nishida S
    J Dermatol Sci; 2020 Sep; 99(3):168-176. PubMed ID: 32693971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma.
    Leman JA; Dick DC; Morton CA
    Clin Exp Dermatol; 2002 Sep; 27(6):516-8. PubMed ID: 12372098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
    Nevala H; Karenko L; Vakeva L; Ranki A
    Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
    Afifi S; Mohamed S; Zhao J; Foss F
    Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.